| 1:00 PM - 1:05 PM | Opening Remarks |
| 1:05 PM - 2:15 PM | SESSION 1: Peptide Therapies |
| 1:05 PM - 1:25 PM | Brad Pentelute, MIT |
| 1:25 PM - 1:45 PM |
Kevin Seibert, Eli Lilly Developing a Novel Platform for Synthetic Peptide Manufacture Using Continuous Synthesis Methodologies |
| 1:45 PM - 2:05 PM | Joint Q&A |
| 2:05 PM - 2:15 PM | "Coffee" Break |
| 2:15 PM - 3:25 PM | SESSION 2: RNA Therapies |
| 2:15 PM - 2:35 PM | Michelle Lynn Hall, Eli Lilly |
| 2:35 PM - 2:55 PM |
Janine Tom, Amgen siRNA as an Emerging Modality |
| 2:55 PM - 3:15 PM | Joint Q&A |
| 3:15 PM - 3:25 PM | "Coffee" Break |
| 3:25 PM - 4:25 PM | SESSION 3: Cell and Gene Therapies |
| 3:25 PM - 3:45 PM | Jennitte Stevens, Amgen |
| 3:45 PM - 4:05 PM |
Nathalie Clement University of Florida From pioneering rAAV to large-scale manufacturing for gene therapy trials |
| 4:05 PM - 4:25 PM | Joint Q&A |
| 4:25 PM - 4:30 PM | Wrap-up Comments |
